New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT05941507
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study tests a new drug called LCB84, which targets a protein (TROP2) found on many cancer cells and delivers a toxic payload directly to them. It is being tested alone and together with an immunotherapy drug (anti-PD-1) in 300 people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drugs can shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Oncology
NOT_YET_RECRUITINGNashville, Tennessee, 37203, United States
Contact
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas Southwestern Medical Center
NOT_YET_RECRUITINGDallas, Texas, 75390, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LCB84 (a drug that targets TROP2 on cancer cells and delivers a chemotherapy-like agent) and an anti-PD-1 antibody (a type of immunotherapy)
What this could lead to
If successful, this could provide a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2), so the safety and effectiveness are not yet proven. Side effects from the drug combination could be significant, and the treatment may not shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.